Date(s) - 12/16/2020
11:00 am - 12:00 pm
Long Acting Injectable PrEP: Time Sensitive Spotlight on Teens
We all celebrate the wonderful news that long acting injectable cabotegravir has been proven to be safe and incredibly efficacious for HIV prevention among adults. But we still have critical work to do with younger folks.
The HPTN-083-1 study (https://www.hptn.org/research/studies/083-01) on injectable cabotegravir for PrEP recently launched in Chicago with the goal of recruiting young (under 18) gay men, transwomen and gender fluid folks (must be male assigned at birth.) While efficacy has been determined in two Phase III studies with adults, this partner study is focusing on teen/adolescent use, with particular interest in safety and acceptability among this group.
It is expected that long acting injectable cabotegravir for prevention will move its way through the FDA approval process in 2021. We could have this approved and ready for use in populations by early 2022.
This train is moving FAST!
We know that many young people don’t wait til their 18th birthdays to have sex, so people under 18 shouldn’t have to wait to get access to long acting injectable cabotegravir for HIV prevention. Let’s recall that adolescent approval for Truvada as PrEP happened six years after the FDA’s adult approval for this intervention.
Let’s do our best to make sure they are on the train and don’t need to wait.
Please join this webinar to learn more about this important study and how you can support awareness and recruitment efforts. Our collective goal is to receive an adolescent indication for long acting injectable cabotegravir at the same time FDA approves the drug for adult use. Time is of the essence.
Dr. Sybil Hosek, Chicago investigator at CORE Center, and young prevention advocates who have participated in injectable PrEP studies